The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Eric Raymond

Department of Medicine

Institute Gustave-Roussy




Name/email consistency: high



  • Department of Medicine, Institute Gustave-Roussy, Villejuif, France. 2000 - 2003
  • INSERM U482, Hôpital Saint Antoine, Paris, France. 2002
  • Institute for Drug Development-Cancer Therapy and Research Center, San Antonio, Texas 78245-3217, USA. 2001


  1. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Raymond, E., Fabbro, M., Boige, V., Rixe, O., Frenay, M., Vassal, G., Faivre, S., Sicard, E., Germa, C., Rodier, J.M., Vernillet, L., Armand, J.P. Ann. Oncol. (2003) [Pubmed]
  2. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Raymond, E., Campone, M., Stupp, R., Menten, J., Chollet, P., Lesimple, T., Fety-Deporte, R., Lacombe, D., Paoletti, X., Fumoleau, P. Eur. J. Cancer (2002) [Pubmed]
  3. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. Raymond, E., Louvet, C., Tournigand, C., Coudray, A.M., Faivre, S., De Gramont, A., Gespach, C. Int. J. Oncol. (2002) [Pubmed]
  4. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. Raymond, E., ten Bokkel Huinink, W.W., Taïeb, J., Beijnen, J.H., Faivre, S., Wanders, J., Ravic, M., Fumoleau, P., Armand, J.P., Schellens, J.H. J. Clin. Oncol. (2002) [Pubmed]
  5. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. Raymond, E., Boige, V., Faivre, S., Sanderink, G.J., Rixe, O., Vernillet, L., Jacques, C., Gatineau, M., Ducreux, M., Armand, J.P. J. Clin. Oncol. (2002) [Pubmed]
  6. Cellular and molecular pharmacology of oxaliplatin. Raymond, E., Faivre, S., Chaney, S., Woynarowski, J., Cvitkovic, E. Mol. Cancer Ther. (2002) [Pubmed]
  7. Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas. Raymond, E., Faivre, S., Weiss, G., McGill, J., Davidson, K., Izbicka, E., Kuhn, J.G., Allred, C., Clark, G.M., Von Hoff, D.D. Clin. Cancer Res. (2001) [Pubmed]
  8. DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs. Raymond, E., Soria, J.C., Izbicka, E., Boussin, F., Hurley, L., Von Hoff, D.D. Invest. New. Drugs (2000) [Pubmed]
  9. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Raymond, E., Faivre, S., Armand, J.P. Drugs (2000) [Pubmed]
WikiGenes - Universities